Related Experiment Videos
[Intermittent androgen blockade in prostatic carcinoma].
1Urologická klinika 1. LF UK a VFN, Praha. j.vit@email.cz
Casopis Lekaru Ceskych
|February 5, 2003
Summary
Intermittent endocrine therapy for prostate cancer may extend survival and improve quality of life by reducing side effects. Further studies are needed to confirm prolonged survival benefits.
Area of Science:
- Oncology
- Endocrinology
Context:
- Prostate cancer treatment often involves continuous androgen ablation, leading to side effects.
- Intermittent endocrine therapy (IET) offers an alternative approach to managing prostate cancer.
Purpose:
- To evaluate the efficacy of intermittent endocrine treatment (IET) in prolonging survival and improving quality of life for prostate cancer patients.
- To assess the impact of IET on delaying progression to androgen independence and mitigating treatment side effects.
Summary:
- IET involves cycles of treatment and off-therapy intervals, with a recommended therapeutic period of 6-9 months.
- The mean off-therapy interval is approximately 50% of the treatment duration.
- The study observed a mean time to disease progression of 32 months.
Impact:
- IET demonstrates potential for inducing apoptotic regressions and improving quality of life, including sexual function.
- While promising, definitive conclusions on prolonged survival require ongoing randomized studies.